retatrutide triple agonist | 99.67% Purity, Third-Party Tested Retatrutide, a triple agonist, delivered

Existing DTC Prescribers

Current licensing and NICE guidance: Semaglutide (Wegovy) is licensed for weight management in adults with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater with at least one weight-related comorbidity

Because peace of mind matters

While 81% of respondents had not personally observed complications in these patients, aspiration due to delayed gastric emptying and subsequently an increased aspiration risk was identified as the primary concern by the majority of respondents

When a patient asks, "Does this work?", the staff can answer from personal experience

GLP-1 has stronger effects on appetite and brain signaling, while GIP has more pronounced effects on fat tissue and glucose-dependent metabolic regulation